Why Did Concordia Healthcare Corp. Shares Fall 50%?

Concordia Healthcare Corp. (TSX:CXR)(NYSE:CXRX) shares have fallen by 50% since September 8th. Is this the opportunity of a lifetime?

The Motley Fool

On the morning of September 8th, Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX) was flying high. It had just announced another big acquisition, one that would increase its earnings per share by 35% in the first year. The U.S.-listed shares opened at US$89, an all-time high.

Fast forward to Friday afternoon, and the shares closed at US$43.90, down more than 50%. So, what exactly happened, and is this a good buying opportunity? We take a look below.

What went wrong?

The bad news started when investors fully digested the new acquisition. Like Concordia’s other purchases, it required a big capital raise, but this one was apparently too much for investors to stomach. The stock fell below US$75 that day.

From there, the shares drifted down further as investors worried about the effects of Concordia’s equity raise. Put simply, a bunch of the company’s shares were about to be sold, and investors got scared this would drive down the stock price. By Friday September 24th, Concordia’s shares were trading for less than US$67.

Then on the following Monday, Democratic lawmakers demanded a subpoena on Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), one that would have forced the company to release details of recent price increases. The Democrats were reacting to the recent uproar over high drug prices, which has become the number one healthcare priority for American voters.

This made Concordia’s shareholders especially nervous, because 100% of the company’s business is in the United States, and profits primarily depend on drug price increases. Concordia’s stock price dropped by about a quarter that day, closing below US$43.

From there, some big stop-loss orders were triggered, sending the shares well below US$40. Bargain hunters then stepped in, leading to a modest recovery.

Is this a buying opportunity?

There are some serious risks that come with an investment in Concordia. First of all, the company is a serial acquirer, which makes the business difficult to value. And when using traditional financial metrics, the stock is very expensive. Thus, an investment in the company requires a lot of faith in management—not unlike an investment in Valeant.

Furthermore, the United States could pass new legislation to control drug prices. Hillary Clinton has proposed some drastic measures, including a US$250/month limit on out-of-pocket drug costs in health insurance plans. Even more modest steps can have a big impact; for example, Medicare can negotiate lower prices for drugs, or the United States could import more pharmaceuticals from Canada. Mrs. Clinton supports these measures as well.

But at the same time, Concordia shares have clearly fallen way too far, which tends to happen when everyone is selling at the same time. And any new legislation would require approval from Congress, which is far from a given. So, if you’re willing to take some risks, Concordia is worth a small slice of your portfolio.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

worker with shovel looks into hole in dirt
Dividend Stocks

Don’t Sell Your Winners Over One Bad Thursday: 2 Canadian Stocks That Are Long-Term Buys

One bad day will not diminish the appeal of two Canadian stocks to long-term investors, including retirees.

Read more »

holding coins in hand for the future
Dividend Stocks

How Dweeby-Sounding “DRIPs” Can Supercharge Your Portfolio Growth

A dividend reinvestment plan can turn small cash payments into more shares. The trick is knowing when your dividend is…

Read more »

a man relaxes with his feet on a pile of books
Dividend Stocks

5 of the Best Canadian Dividend Stocks to Buy This Month

These best Canadian dividend stocks have reliable distribution payment and growth histories, and sustainable payouts.

Read more »

warehouse worker takes inventory in storage room
Dividend Stocks

This 5.6% Dividend Stock Pays Cash Every Single Month

This TSX-listed monthly dividend stock’s attractive 5.6% dividend yield, growing rental income, and expanding property portfolio could make it a…

Read more »

Trans Alaska Pipeline with Autumn Colors
Energy Stocks

TFSA Income: A Solid Dividend Stock Down 15% to Buy Before It Bounces Back

This stock has increased its dividend annually for more than three decades.

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Investing

3 Top Stocks for TFSA Investors to Buy Now

These stocks can help you avoid selling at a loss by prioritizing high-quality companies with sustainable growth prospects.

Read more »

Aircraft Mechanic checking jet engine of the airplane
Dividend Stocks

Exchange Income vs. Cargojet: Which Aviation Stock Fits a Long-Term Portfolio?

Both businesses depend on keeping aircraft busy. Exchange Income’s mix of essential routes and manufacturing gives it the edge for…

Read more »

man touches brain to show a good idea
Dividend Stocks

1 No Brainer Canadian Stock to Buy and Hold Forever

CN stock is up 35% in 2026, yet Q3 earnings jumped 18% on only 4% more volume. See why this…

Read more »